Yuanyuan Zhao

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Venues

Cancer communications (London, England)

Journal for immunotherapy of cancer

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Yuxiang Ma, Jinhui Xue, Yuanyuan Zhao, Yang Zhang, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ye Guo, Qun Li, Xiaoxiao Ge, Jie Sun, Bangyong Zhang, Yuhan Zhang, Jinyuan Xiao, Li Zhang, Hongyun Zhao
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. Journal for immunotherapy of cancer 11 (6) (2023)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) (2022)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) 43 (2) (2022)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) 43 (2) (2022)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) 43 (2) (2022)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) 43 (2) (2022)
Yunpeng Yang, Ting Zhou, Xiaozhong Chen, Jingao Li, Jianji Pan, Xiaohui He, Lizhu Lin, Ying-Rui Shi, Weineng Feng, Jianping Xiong, Kunyu Yang, Qitao Yu, Qunling Zhang, Desheng Hu, Yan Sun, Guangyuan Hu, Ping Li, Liangfang Shen, Qin Lin, Ben Zhang, Xiao Qu, Jianjun Zou, Li Zhang, Wenfeng Fang, Yuanyuan Zhao
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). Journal for immunotherapy of cancer 9 (12) (2022)
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer communications (London, England) 43 (2) (2022)
Cuiyun Su, Maojian Chen, Guanxuan Chen, Yajun Li, Ning Li, Zhihuang Hu, Xiao Hu, Yuanyuan Zhao, Qitao Yu, Wei Jiang
Practices and Hindrances in Cancer Pain Management: Results of a National Multi-Cancer Center Survey Among Healthcare Professionals in China. Cancer management and research 13 (2021)

Yuanyuan Zhao.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yuanyuan Zhao